Fig. 3

A₄₀-POs treatment reduces cerebral Aβ burden in APP/PS1 mice. ELISA measurement of whole-brain (a) and plasma (b) Aβ levels at 2 h post injection, comparing wild-type (WT), sham, angiopep-2 alone (A₁), pristine P[(OEG)₁₀ MA]₂₀-PDPA₁₂₀ polymersomes (A₀-POs), and angiopep-2-functionalized polymersomes with ligand densities of 40 (A₄₀-POs) or 200 (A₂₀₀-POs) per vesicle. PET‒CT visualization (c) in wild-type (WT) and APP/PS1 (pre- and 12 h post A₄₀-POs administration) mice with [¹⁸ F] AV-45 (2.8--3.2 MBq) tracer. Quantified SUV (d) reductions confirm significant Aβ clearance. 3D rendering imaging (e) of the brain after tissue clearing shows reduced Aβ signals in 12 h post A₄₀-POs injected mice. Brain parcellation into 14 regions was performed according to the Allen Brain Atlas, revealing Aβ distribution across brain regions (f). A₄₀-POs treatment induced 41% Aβ volume reduction in total after 12 h of treatment (g) (data expressed as mean ± SEM). Heat map representation of Aβ fluorescence intensity across a single coronal brain layer (h). Tissue-clearing and PET-CT imaging were conducted three repeats per group (n = 3). Statistical significance for graphs a, b, d was determined via one-way analysis of variance (ANOVA), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001